한글목차

세계 중화 항체 시장의 미래는 병원 및 클리닉, 연구기관, 진단 실험실, 제약회사 등 다양한 시장에서 기회로 인해 유망합니다. 세계 중화 항체 시장은 2025-2031년간 연평균 11.2%의 성장률을 보일 것으로 예상됩니다. 이 시장의 주요 촉진요인은 류마티스 관절염, 다발성 경화증, 루푸스 등 자가면역질환의 유병률 증가, 감염성 질환의 유병률 증가, 기존 백신 및 약물 대비 항체 기반 치료의 이점에 대한 인식이 높아지는 것 등입니다.

• Lucintel은 용도별로는 치료 분야가 예측 기간 동안 가장 큰 규모를 유지할 것으로 예상하고 있습니다.
• 최종 용도 카테고리에서 제약회사는 계속해서 가장 큰 부문이 될 것입니다.
• 지역별로 보면, 북미는 대기업의 존재와 탄탄한 헬스케어 시스템으로 인해 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다.

중성화 항체 시장의 전략적 성장 기회

중화 항체 시장의 전략적 성장은 다양한 치료 분야로의 적용에 의해 촉진되고 있습니다. 기업들은 감염성 질환, 종양, 개인 맞춤형 의료에서 주요 성장 기회를 발견하고 시장 입지를 확대하고 있습니다.

• 감염병 치료: 감염병, 특히 코로나19 증가로 인해 중화 항체 분야는 큰 성장 기회를 맞이하고 있습니다. 기업들은 세계 수요에 대응하기 위해 신속한 승인 획득과 항체 대량 생산에 집중하고 있습니다.
• 암 분야: 중화항체의 주요 성장 분야인 암 분야는 치료하기 어려운 암 환자에게 유망한 치료법을 제공하는 표적 치료제로서 계속 성장하고 있습니다. 암세포를 선택적으로 공격할 수 있는 항체의 개발이 주요 촉진요인입니다.
• 자가면역질환: 중화항체는 자가면역질환 치료에 점점 더 많이 사용되고 있으며, 부작용을 최소화하고 환자의 예후를 개선하는 표적 치료법을 제공합니다.
• 만성질환: 당뇨병, 심혈관 질환 등 만성질환에서 중화 항체 사용이 증가하면서 장기적인 건강 결과를 개선할 수 있는 새로운 치료 옵션을 제공합니다.
• 맞춤형 의료: 맞춤형 의료의 발전으로 환자 개개인의 유전자 프로파일에 맞는 중화항체를 개발할 수 있는 기회가 생겨나면서 다양한 질병에 대한 치료의 정확성과 효능이 향상되고 있습니다.

이러한 전략적 성장 기회는 기술 혁신을 촉진하고 다양한 치료 영역에서 중화 항체 사용을 확대하여 시장을 지속적으로 확대할 수 있는 기회를 제공합니다.

중화 항체 시장 성장 촉진요인 및 과제

중화 항체 시장은 기술 발전, 규제 상황, 경제 상황 등 다양한 요인의 영향을 받습니다. 이러한 시장 성장 촉진요인 및 과제는 향후 시장의 성장 궤도를 형성하는 데 매우 중요한 역할을 할 것입니다.

중화 항체 시장을 주도하는 요인은 다음과 같습니다.

• 코로나19 치료제에 대한 수요 증가: 세계 팬데믹으로 인해 중화항체, 특히 코로나19 치료제에 대한 수요가 급증하고 있으며, 이는 연구 증가와 신속한 규제 당국의 승인으로 이어지고 있습니다.
• 생명공학의 발전: 생명공학의 끊임없는 발전으로 보다 효과적이고 표적화된 중화 항체 개발이 가능해져 시장 성장을 견인하고 있습니다.
• 암 치료: 암 치료에서 중화 항체 사용 확대는 주요 촉진요인이며, 유망한 임상 결과는 새로운 승인과 시장 확대로 이어질 것입니다.
• 정부 지원 및 자금 지원: 각국 정부는 항체 연구, 특히 감염 및 암 분야의 항체 연구에 대한 자금 지원을 늘려 연구개발 노력을 촉진하고 시장 성장을 가속화하고 있습니다.
• 공동 파트너십: 제약회사와 연구기관의 공동연구를 통해 새로운 항체 치료제의 신속한 개발 및 상용화가 가능해지고 있습니다.

중화 항체 시장의 과제는 다음과 같습니다.

• 높은 개발 비용: 높은 개발 비용: 중화 항체 개발에는 연구개발과 임상시험에 많은 투자가 필요하기 때문에 중소기업에게는 큰 부담으로 작용하고 있습니다.
• 규제적 장애물: 생물학적 제제의 복잡한 규제 상황에 대응하는 것은 제품 승인을 지연시킬 수 있으며, 이는 새로운 치료제 시장 출시 시간에 영향을 미칠 수 있습니다.
• 제조 복잡성: 중화 항체 생산은 복잡한 공정이 수반되기 때문에 특히 신흥 시장에서는 생산 규모 확대가 과제입니다.

중화 항체 시장은 기술 발전, 정부 지원, 새로운 치료법에 대한 수요 증가에 힘입어 성장하고 있습니다. 그러나 시장이 잠재력을 충분히 발휘하기 위해서는 높은 개발 비용과 규제 장벽과 같은 문제를 해결해야 합니다.

목차

제1장 주요 요약

제2장 세계의 중화 항체 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 중화 항체 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 중화 항체 시장, 표적 바이러스별
  • SARS-CoV-2
  • HIV
  • 인플루엔자
  • 에볼라
  • 지카열
  • C형 간염
• 세계의 중화 항체 시장, 항체 유형별
  • 단일클론항체
  • 다중클론항체
• 세계의 중화 항체 시장, 용도별
  • 치료
  • 진단
  • 연구개발
  • 기타
• 세계의 중화 항체 시장, 최종 용도별
  • 병원 및 진료소
  • 연구기관
  • 진단 실험실
  • 제약회사
  • 기타

제4장 시장 동향과 예측 분석(2019-2031년), 지역별

• 세계의 중화 항체 시장, 지역별
• 북미의 중화 항체 시장
• 유럽의 중화 항체 시장
• 아시아태평양의 중화 항체 시장
• 기타 지역의 중화 항체 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 중화 항체 시장 성장 기회, 표적 바이러스별
  • 세계의 중화 항체 시장 성장 기회, 항체 유형별
  • 세계의 중화 항체 시장 성장 기회, 용도별
  • 세계의 중화 항체 시장 성장 기회, 최종 용도별
  • 세계의 중화 항체 시장 성장 기회, 지역별
• 세계 중화 항체 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 중화 항체 시장 생산능력 확대
  • 세계의 중화 항체 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증과 라이선싱

제7장 주요 기업 개요

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

영문목차

The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets. The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the growing incidence of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus, the rising prevalence of infectious diseases, and the increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

• Lucintel forecasts that, within the application category, the therapeutic segment will remain the largest segment over the forecast period.
• Within the end-use category, pharmaceutical companies will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of major firms and a robust healthcare system across the country.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neutralizing Antibody Market

The neutralizing antibody market is transforming due to technological innovations and a shift in healthcare priorities. These emerging trends are reshaping how companies develop and commercialize neutralizing antibody therapies globally.

• Increased Focus on COVID-19 Antibodies: With the global pandemic, there has been a surge in research for neutralizing antibodies targeting COVID-19. Companies are fast-tracking clinical trials and securing emergency use authorizations, making this a dominant trend in the market.
• Expansion in Oncology Treatments: Neutralizing antibodies are being increasingly utilized in oncology treatments. Companies are developing targeted therapies that attack specific cancer cells, offering more effective and less toxic treatment options.
• Personalized Medicine: The move toward personalized medicine is driving the development of antibodies tailored to individual patients' needs, particularly in cancer and autoimmune disorders. This trend enhances treatment efficacy and reduces side effects.
• Collaborations and Partnerships: The industry is seeing a rise in collaborations between biotech firms, pharmaceutical companies, and research institutions. These partnerships are speeding up innovation and enabling broader market access for new therapies.
• Technological Advancements in Biologics: Advancements in biologics manufacturing, including the use of cell-based and gene-editing technologies, are improving the efficiency and scalability of neutralizing antibody production, lowering costs, and boosting supply.

These trends are reshaping the neutralizing antibody market, with a focus on innovation, personalized treatments, and strategic collaborations, leading to more effective therapies and broader market penetration.

Recent Developments in the Neutralizing Antibody Market

The neutralizing antibody market has seen major advancements across various therapeutic areas, with key developments driving growth. Companies are focusing on innovation, partnerships, and regulatory milestones to capitalize on emerging opportunities in this fast-evolving market.

• COVID-19 Antibody Approvals: Several neutralizing antibodies have received emergency use authorizations for COVID-19 treatment, with major pharmaceutical companies launching new products that show efficacy in reducing viral loads.
• Oncology Innovations: Breakthroughs in neutralizing antibodies for oncology have been achieved, with new therapies targeting specific cancer cells, showing high effectiveness in clinical trials and receiving regulatory approvals in major markets.
• Collaborative Research Initiatives: There has been an increase in collaborative initiatives between biotech companies and academic institutions, particularly in the U.S. and Europe, aimed at accelerating antibody research for infectious diseases and cancers.
• Technological Advances in Manufacturing: Advances in biologics manufacturing have reduced production costs and improved scalability, making neutralizing antibodies more accessible and affordable for a wider range of treatments.
• Government Support for Biotechnology: Governments worldwide are increasing funding and support for biotechnology research, driving growth in the neutralizing antibody market as companies receive grants and tax incentives for R&D.

These developments are significantly impacting the neutralizing antibody market, fostering innovation, improving treatment outcomes, and enabling companies to capture new market opportunities globally.

Strategic Growth Opportunities for Neutralizing Antibody Market

Strategic growth in the neutralizing antibody market is being driven by its applications across various therapeutic areas. Companies are identifying key growth opportunities in infectious diseases, oncology, and personalized medicine, allowing them to expand their market presence.

• Infectious Disease Treatments: The rise of infectious diseases, particularly COVID-19, has created immense growth opportunities for neutralizing antibodies. Companies are focusing on fast-tracked approvals and large-scale production of antibodies to meet global demand.
• Oncology: Oncology remains a major growth area for neutralizing antibodies, with targeted therapies offering promising outcomes for patients with difficult-to-treat cancers. The development of antibodies that can selectively attack cancer cells is a key growth driver.
• Autoimmune Diseases: Neutralizing antibodies are increasingly being used in the treatment of autoimmune diseases, providing targeted therapies that minimize side effects and improve patient outcomes.
• Chronic Diseases: The use of neutralizing antibodies in chronic diseases, such as diabetes and cardiovascular conditions, is growing, offering new treatment options that improve long-term health outcomes.
• Personalized Medicine: Advances in personalized medicine are creating growth opportunities for neutralizing antibodies tailored to individual patients' genetic profiles, enhancing the precision and efficacy of treatments across various diseases.

These strategic growth opportunities are driving innovation and expanding the use of neutralizing antibodies across diverse therapeutic areas, positioning the market for continued expansion.

Neutralizing Antibody Market Driver and Challenges

The neutralizing antibody market is influenced by a variety of factors, including technological advancements, regulatory landscapes, and economic conditions. These drivers and challenges play a crucial role in shaping the market's future growth trajectory.

The factors responsible for driving the neutralizing antibody market include:

• Rising Demand for COVID-19 Therapies: The global pandemic has fueled demand for neutralizing antibodies, particularly for COVID-19 treatments, leading to increased research and rapid regulatory approvals.
• Advancements in Biotechnology: Continuous advancements in biotechnology are enabling the development of more effective and targeted neutralizing antibodies, driving market growth.
• Oncology Therapies: The expanding use of neutralizing antibodies in oncology is a major driver, with promising clinical results leading to new approvals and market expansion.
• Government Support and Funding: Governments are increasing funding for antibody research, particularly in infectious diseases and oncology, boosting R&D efforts and accelerating market growth.
• Collaborative Partnerships: Collaborations between pharmaceutical companies and research institutions are enabling faster development and commercialization of new antibody therapies.

Challenges in the neutralizing antibody market are:

• High Development Costs: The development of neutralizing antibodies requires significant investment in R&D and clinical trials, posing a challenge for smaller companies.
• Regulatory Hurdles: Navigating the complex regulatory landscape for biologics can slow down product approvals, impacting time-to-market for new therapies.
• Manufacturing Complexity: The production of neutralizing antibodies involves complex processes, making scaling up manufacturing a challenge, particularly in emerging markets.

The neutralizing antibody market is driven by technological advancements, government support, and rising demand for novel therapies. However, challenges such as high development costs and regulatory hurdles must be addressed for the market to reach its full potential.

List of Neutralizing Antibody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neutralizing antibody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutralizing antibody companies profiled in this report include-

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

Neutralizing Antibody by Segment

The study includes a forecast for the global neutralizing antibody market by target virus, antibody type, application, end use, and region.

Neutralizing Antibody Market by Target Virus [Analysis by Value from 2019 to 2031]:

• SARS-CoV-2
• HIV
• Influenza
• Ebola
• Zika
• Hepatitis C

Neutralizing Antibody Market by Antibody Type [Analysis by Value from 2019 to 2031]:

• Monoclonal Antibodies
• Polyclonal Antibodies

Neutralizing Antibody Market by Application [Analysis by Value from 2019 to 2031]:

• Therapeutics
• Diagnostics
• Research and Development
• Others

Neutralizing Antibody Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals and Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Others

Neutralizing Antibody Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neutralizing Antibody Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are highlights of recent developments by major neutralizing antibody producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., recent advancements in neutralizing antibody research are driven by increased investment in COVID-19 therapies. The FDA has fast-tracked approvals for several monoclonal antibodies, further boosting the market as companies focus on cancer therapies and infectious disease treatments.
• China: In China, the neutralizing antibody market is witnessing rapid growth as local biotech companies invest in R&D and clinical trials for COVID-19 antibodies. Government support for innovation in biologics is accelerating the commercialization of neutralizing antibodies across multiple therapeutic areas.
• Germany: Germany's neutralizing antibody market is driven by collaborations between academic institutions and biotech companies. The country has made significant strides in developing antibodies for oncology and infectious diseases, with a focus on personalized medicine and targeted therapies.
• India: India's neutralizing antibody market is growing due to increased efforts in biotechnology and biopharma. The country is seeing a rise in clinical trials for COVID-19 therapies and a growing focus on antibody-based treatments for autoimmune and chronic diseases.
• Japan: Japan's neutralizing antibody market is experiencing growth driven by government initiatives to advance biotechnology and biopharmaceutical research. Major pharmaceutical companies are focusing on innovative monoclonal antibody treatments for cancer and other chronic conditions, contributing to market expansion.

Features of the Global Neutralizing Antibody Market

Market Size Estimates: Neutralizing antibody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Neutralizing antibody market size by target virus, antibody type, application, end use, and region in terms of value ($B).

Regional Analysis: Neutralizing antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different target virus, antibody type, application, end use, and regions for the neutralizing antibody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutralizing antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neutralizing antibody market by target virus (SARS-CoV-2, HIV, influenza, Ebola, zika, and hepatitis C), antibody type (monoclonal antibodies and polyclonal antibodies), application (therapeutics, diagnostics, research and development, and others), end use (hospitals and clinics, research institutes, diagnostic laboratories, pharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutralizing Antibody Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Neutralizing Antibody Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Neutralizing Antibody Market by Target Virus
  • 3.3.1: SARS-CoV-2
  • 3.3.2: HIV
  • 3.3.3: Influenza
  • 3.3.4: Ebola
  • 3.3.5: Zika
  • 3.3.6: Hepatitis C
• 3.4: Global Neutralizing Antibody Market by Antibody Type
  • 3.4.1: Monoclonal Antibodies
  • 3.4.2: Polyclonal Antibodies
• 3.5: Global Neutralizing Antibody Market by Application
  • 3.5.1: Therapeutics
  • 3.5.2: Diagnostics
  • 3.5.3: Research and Development
  • 3.5.4: Others
• 3.6: Global Neutralizing Antibody Market by End Use
  • 3.6.1: Hospitals and Clinics
  • 3.6.2: Research Institutes
  • 3.6.3: Diagnostic Laboratories
  • 3.6.4: Pharmaceutical Companies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Neutralizing Antibody Market by Region
• 4.2: North American Neutralizing Antibody Market
  • 4.2.1: North American Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.2.2: North American Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.3: European Neutralizing Antibody Market
  • 4.3.1: European Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.3.2: European Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.4: APAC Neutralizing Antibody Market
  • 4.4.1: APAC Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.4.2: APAC Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.5: ROW Neutralizing Antibody Market
  • 4.5.1: ROW Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.5.2: ROW Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neutralizing Antibody Market by Target Virus
  • 6.1.2: Growth Opportunities for the Global Neutralizing Antibody Market by Antibody Type
  • 6.1.3: Growth Opportunities for the Global Neutralizing Antibody Market by Application
  • 6.1.4: Growth Opportunities for the Global Neutralizing Antibody Market by End Use
  • 6.1.5: Growth Opportunities for the Global Neutralizing Antibody Market by Region
• 6.2: Emerging Trends in the Global Neutralizing Antibody Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neutralizing Antibody Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutralizing Antibody Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Regeneron Pharmaceuticals
• 7.2: Eli Lilly and Company
• 7.3: AstraZeneca
• 7.4: GlaxoSmithKline
• 7.5: Sanofi
• 7.6: Roche
• 7.7: Novartis
• 7.8: Merck
• 7.9: Pfizer
• 7.10: Johnson & Johnson